New data shows AstraZeneca's combination asthma treatment Symbicort improved quality of life and satisfaction for patients better than the drug's two main ingredients do separately. Symbicort, recently approved for long-term use, is a combination of the inhaled corticosteroid budesonide and the beta agonist formoterol fumarate dehydrate.

Full Story:

Related Summaries